PBM (Psyence Biomedical Ltd. Common Shares) stock: $6.62, $25.3M market cap, $7.4M cash, $28.3M EV, $25.5M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$6.62
Market cap
$25.3M
Cash
$7.4M
Enterprise value
$28.3M
Balance sheet
Cash
$7.4M
Debt
$10.4M
Net cash
-$3.0M
Enterprise value
$28.3M
Basic shares
3.8M shares
Fully diluted shares
3.9M shares
Fully diluted market cap
$25.5M
Cash per share
$1.95
Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.
Price history
Loading PBM daily closes…
Loading price history…
Pipeline assets
Psilocybin-based product candidates
Stage not disclosed · Active
Target 5-HT2A
Status note The company has no registered products on the market; its new potential psilocybin-based product candidates are either in the preclinical or clinical development phase. The filing names no specific candidates, trials, phases, or indications in the provided excerpts.
Per-asset detail extracted from the 20-F filed 2026-06-22. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.